FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden

hours per response:

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Chien Jennifer  (Last) (First) (Middle)  C/O RHYTHM PHARMACEUTICALS, INC.  222 BERKELEY STREET, 12TH FLOOR  (Street)				3. D 02/	2. Issuer Name and Ticker or Trading Symbol RHYTHM PHARMACEUTICALS, INC. [RYTM]  3. Date of Earliest Transaction (Month/Day/Year) 02/09/2023  4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, Head of North America  6. Individual or Joint/Group Filing (Check Applicable Line)					
BOSTON (City)			02116 (Zip)		-	X Form filed by One Report Form filed by More than C Person										Ü			
		Tabl	le I - Noi	n-Deri\	/ative	Sec	curiti	es Ac	quired,	Dis	posed o	of, or E	ene	ficial	y Owne	d			
Date			2. Trans Date (Month/	Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amou Securiti Benefici Owned	es ally Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) (D)	or	Price	Transac (Instr. 3	ction(s)			(Instr. 4)	
Common Stock			02/09	9/2023				М		3,438	3 <i>A</i>		(1)	4,	4,748		D		
Common Stock 02			02/09	9/2023	/2023			S <sup>(2)</sup>		1,192	2 I	)	\$27.6	3,556			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any			3A. Deeme Execution if any (Month/Da	Date, Transaction Code (Ins			ion of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nu of	ımber					
Restricted Stock Units	(1)	02/09/2023			M			3,438	(3)		(3)	Commo	3,	,438	\$0	10,312	2	D	

## **Explanation of Responses:**

- $1. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ Issuer \ common \ stock.$
- 2. The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- 3. The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.

/s/ Hunter Smith, Attorney-in-Fact for Jennifer Chien

02/13/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.